WO2006029579A1 - Composition pharmaceutique orale pour le transport cible de complexe de platine dans la region colorectale, procede de fabrication, et utilisation comme medicament - Google Patents

Composition pharmaceutique orale pour le transport cible de complexe de platine dans la region colorectale, procede de fabrication, et utilisation comme medicament Download PDF

Info

Publication number
WO2006029579A1
WO2006029579A1 PCT/CZ2005/000070 CZ2005000070W WO2006029579A1 WO 2006029579 A1 WO2006029579 A1 WO 2006029579A1 CZ 2005000070 W CZ2005000070 W CZ 2005000070W WO 2006029579 A1 WO2006029579 A1 WO 2006029579A1
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
platinum complex
optionally
pharmaceutical composition
granulate
Prior art date
Application number
PCT/CZ2005/000070
Other languages
English (en)
Inventor
Ales Franc
Petr Sova
Original Assignee
Pliva-Lachema A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva-Lachema A.S. filed Critical Pliva-Lachema A.S.
Priority to AT05785547T priority Critical patent/ATE491445T1/de
Priority to US11/574,929 priority patent/US7655697B2/en
Priority to EP05785547A priority patent/EP1802295B1/fr
Priority to JP2007531577A priority patent/JP2008513383A/ja
Priority to DE602005025382T priority patent/DE602005025382D1/de
Priority to PL05785547T priority patent/PL1802295T3/pl
Publication of WO2006029579A1 publication Critical patent/WO2006029579A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2873—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Definitions

  • the invention relates to an oral pharmaceutical composition for a targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof.
  • Colorectal carcinoma is a malignant tumor of the colon, in Europe belonging to the most widespread types of tumor diseases. Annually, almost 7 500 new cases of this disease are diagnosed and each year more than 4 000 of patients die of this disease. Over 50 % of these tumors are localized in the rectum and 20 % of them attack sigmoideum. Only about 15 % of tumors were found in the colon proper, of them about 6 to 8 % in the colon transversum and about 6 to 7 % in the colon descendens. Despite differences in their anatomic location, the mentioned tumors are regarded as affection of one organ and are denoted as the colorectal carcinoma. Women suffer from colorectal carcinoma more often in the region of colon whereas men are more often affected in the rectal region.
  • Colorectal carcinoma Clinical symptoms of colorectal carcinoma are manifested by its localization, magnitude of the mechanical obstruction and the overall response of the organism.
  • the enterostenosis manifests itself by meteorism, change in defecation habits, colical pain, and in some cases by sudden ileus.
  • An exulceration of the tumor manifests itself by microscopic or macroscopic bleeding and subsequent anemia.
  • platinum complexes Another possible application of platinum complexes is the rectal administration in which the platinum complex avoids the aggressive medium of the gastrointestinal tract and after absorption by the rectal mucosa it passes via the portal system directly into the systemic blood circulation.
  • the possibility of rectal application of a tetravalent platinum complex has been described in US 6 033 683.
  • oral administration of platinum complexes represents the most comfortable way for the patient and therefore oral application of a solid dosage form of a platinum complex, enabling release of the platinum complex only in the region of colon appears as very prospective and promising.
  • Such oral colonic application of drugs has its history in application of antirheumatics or in protection of mucous membranes of the gastrointestinal tract by administration of peptides and proteins.
  • drugs or protective substances are applied orally in the form of their conjugates with auxiliary substances, particularly in the form of azo conjugates, cyclodextrin conjugates, glycoside conjugates, glucuronate conjugates, dextran conjugates, polypeptide conjugates and conjugates with polymers, or in a form protected by degradable polymer coating, particularly by a pH-sensitive or biodegradable polymer coating, or in a form sealed in capsules of a biodegradable polymer, preferably sealed in hard capsules, or in the form of a system of anchored drug or protective substance, preferably in the form of a biodegradable polymer and hydrogel matrices, or in the form of a pH-sensitive polymer matrices. All these systems protect the orally applied drug or protective substance from the aggressive medium of the gastrointestinal tract before it enters the large intestine.
  • this invention discloses an oral pharmaceutical composition for a targeted transport of a platinum complex into the colorectal region.
  • an oral pharmaceutical composition for a targeted transport of a platinum complex into the colorectal region characterized in that it comprises a mixture of active substance platinum complex of general formula I
  • A each independently is an -NH 3 group or an amino group containing 1 to 18 carbon atoms
  • B each independently is a halogen atom, a hydroxy group or a COOR group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1 to 10 carbon atoms or functional derivatives of these groups, and
  • X each independently is a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X together form a dicarboxylate group containing 2 to 20 carbon atoms, and at least one excipient selected from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is optionally compressed into a tablet or contained in a capsule, and this tablet or capsule is optionally coated with a biodegradable layer and/or an outer pH-sensitive colonic layer.
  • a mixture of the platinum complex of general formula I and at least one excipient selected from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, is advantageously prepared in the form of a granulate, obtained by granulation of the water- wetted mixture of the mentioned platinum complex of general formula I and at least one of the above-mentioned excipients.
  • the oral pharmaceutical composition is advantageously provided in the form of a tablet, obtained by compression of a mixture of the platinum complex of general formula I and at least one excipient from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, and optionally coated with a biodegradable layer, this tablet being coated with an outer pH-sensitive colonic layer.
  • a saccharide oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide
  • a lubricant and/or disintegrant optionally coated with a biodegradable layer, this tablet being coated with an outer pH-sensitive colonic layer.
  • the oral pharmaceutical composition is advantageously provided in the form of a capsule containing a mixture of the platinum complex of general formula I and at least one excipient from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally lubricants and/or disintegrants, this capsule being made of material enabling release of the platinum complex of general formula I only in the large intestine.
  • the oral pharmaceutical composition is advantageously provided in the form of a capsule containing a mixture of the platinum complex of general formula I and at least one excipient from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, this capsule being coated with a biodegradable layer and/or an outer pH-sensitive colonic layer.
  • the oral pharmaceutical composition is advantageously provided in the form of a mixture of the platinum complex of general formula I and at least one excipient from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is coated with a biodegradable layer and/or an outer pH-sensitive layer.
  • excipient from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is coated with a biodegradable layer and/or an outer pH-sensitive layer.
  • the oral pharmaceutical composition is advantageously provided in the form of a mixture of the platinum complex of general formula I and at least one excipient from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is coated with a biodegradable layer and/or an outer pH-sensitive layer, and is contained in a capsule.
  • excipient from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is coated with a biodegradable layer and/or an outer pH-sensitive layer
  • the invention also relates to a method of manufacturing the above-mentioned oral pharmaceutical composition, characterized in that the platinum complex of general formula I is mixed with at least one excipient from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide, mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally with a lubricant and/or disintegrant, whereupon the obtained mixture is optionally wetted with water and granulated to a granulate, and the obtained mixture or the obtained granulate, after optional addition of a lubricant and/or disintegrant, is optionally compacted into tablets or is filled into capsules, and the obtained mixture or the obtained granulate or the obtained tablets or the obtained capsules are optionally coated with a biodegradable layer and/or with an outer pH-sensitive colonic layer.
  • the platinum complex of general formula I is mixed with at least
  • the granulation of the water- wetted mixture is advantageously carried out in an apparatus in which the surfaces in contact with the mixture to be granulated are inert toward this mixture.
  • the compacting of the mixture or the granulate into tablets or filling of the mixture or the granulate into capsules is advantageously carried out in an apparatus in which the surfaces in contact with the mixture or with the granulate during their compacting or filling are inert toward this mixture or toward this granulate.
  • the coating of the mixture or granulate or tablets is advantageously carried out in an apparatus in which the surfaces in contact with the mixture, granulate or tablets to be coated are coated with an inert polymer.
  • the invention also relates to the above-mentioned oral pharmaceutical composition or this composition prepared by the above-described manner, for use as medicament for treatment of colorectal carcinoma.
  • the composition of the oral pharmaceutical composition according to the invention guarantees an excellent stability of the tetravalent platinum complex as well as its colonic release, i.e. release only in the colonic region, in oral administration of solid dosage form.
  • the literature Pulharma Polymers, Vol. 7, October 2000
  • 50 to 65 % of the active substance is released after 6 hours and 85 to 100 % of the active substance is released after 12 hours.
  • This passage lasts for about 2 to 4 hours in the stomach at pH 1 to 5, then for about 3 to 5 hours in the small intestine at pH 5.5 to 7, and finally in the large intestine at pH about 6 to 7.5.
  • the protective excipients that are present in the pharmaceutical composition according to the invention together with the platinum complex of general formula I and form conjugates with this complex, are as such resistant to enzymatic decomposition in the region of stomach and small intestine, and thus they protect the platinum complex from its premature release in these regions.
  • the content of these protective excipients is at least 5 % by weight, based on the total weight of the mixture with the platinum complex.
  • Another excipient that may be contained together with the platinum complex in the pharmaceutical composition according to the invention is a modified polysaccharide.
  • This excipient represents only a binder without any effective protective function.
  • the content of this binder is at least 2 % by weight, based on the total weight of the mixture with the platinum complex.
  • This binder need not be necessarily present if the binding properties of the above-mentioned protecting excipients in their mixing with water are utilized.
  • the mentioned mixture contains the platinum complex with only the mentioned binding excipient formed by a modified polysaccharide, the targeted colonic release of the platinum complex has to be ensured by coating the mentioned mixture with a biodegradable layer and/or an outer pH-sensitive colonic layer.
  • the pharmaceutical composition contains a saccharide and/or oligosaccharide as a filler and the pharmaceutical composition contains neither of the mentioned protective excipients.
  • the mixture of the platinum complex contains at least one of the above-mentioned protective excipients such as polysaccharides, mucopolysaccharides, proteins, oligoproteins, polyproteins, mucoproteins, peptides, oligopeptides and polypeptides, it is possible to protect the complex from a more intense release by coating the mixture with a biodegradable layer and/or by an outer pH-sensitive colonic layer.
  • Representative preferred polysaccharides, mucopolysaccharides, proteins, oligoproteins, polyproteins, mucoproteins, peptides, oligopeptides and polypeptides include e.g. amylose, xylan, inulin, dextrin, cyclodextrin, dextrin, dextran esters, chytosan, arabinogalactan, gum guar, glucuronate, pectin, amylopectin, polyaspartam, chondroitin sulfate, hyaluronic acid and collagen.
  • a modified polysaccharide may be e.g. a modified starch.
  • the oral pharmaceutical composition according to the invention may contain at least one pharmaceutically acceptable lubricant.
  • a suitable lubricant magnesium stearate is advantageously used in an amount equal to at least 0.1 % by weight, based on the total weight of the pharmaceutical composition mixture.
  • the oral pharmaceutical composition according to the invention may contain at least one pharmaceutically acceptable disintegrant, advantageously modified polysaccharides.
  • Such disintegrant is advantageously maize and/or wheat and/or rice and/or potato starch, preferably used in an amount of at least 3 % by weight, more preferably 3 to 20 % by weight, based on the total weight of the pharmaceutical composition mixture.
  • the biodegradable layer optionally coating the oral composition mixture as such or optionally coating a tablet into which this mixture is compacted or optionally coating a capsule containing this mixture, consists of polysaccharides or proteins and their derivatives which before entering the large intestine resist the enzymes of the digestive tract but afterwards undergo fission by action of the bacterial microflora present in the large intestine.
  • the small intestine regions there are colonies of mostly aerobic microflora whereas the large intestine contains an anaerobic bacterial microflora. This specific microflora in the large intestine induces hydrolysis and reduction.
  • Substances, undergoing degradation in this area include e.g.
  • synthetic polymers such as e.g. ethyl cellulose, HEC, MPC, MC and HPMC.
  • the outer pH-sensitive colonic layer optionally coating the oral composition mixture as such, or coating a tablet into which this mixture is compacted, or coating a capsule containing this mixture, consists of pH-sensitive polymers that form membranes resisting the pH-values in the gastrointestinal tract but dissolve at pH values between 6 and 7.
  • pH-sensitive polymers are e.g. acrylate or methacrylate polymers and copolymers of the EUDRAGIT S and EUDRAGIT FS type or hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and also their combinations with suitable reagents such as wetting agents and softeners, pigments and lubricants.
  • HPMCAS hydroxypropyl methyl cellulose acetate succinate
  • this granulate in case of a granulate comprising a mixture of the platinum complex with at least one excipient from the above-mentioned group, this granulate, after mixing with a lubricant and a disintegrant, is filled either into a capsule that afterwards may be coated with an outer pH-sensitive colonic layer, using in this case a gelatin or HPMC capsule, or is filled into a capsule that had been modified in advance for the colonic application.
  • Such modification may particularly consist in that the capsule is made of material, undergoing degradation only by enzymatic action in the colon, such as chytosan, or the capsule body is made of material, resisting the medium of stomach and small intestine but the cap of the capsule is made of material which is dissolved or degraded by action of microflora and at pH 6 to 7 in the colonic region, such material being variously substituted celluloses or acrylate polymers.
  • the granulate or tablet may also be protected by a layer which either directly protects the platinum complex from the medium of stomach and small intestine or will protect the platinum complex from a pH-sensitive polymer coating that allows specific colonic release of the platinum complex but is not compatible with the platinum complex.
  • a layer which either directly protects the platinum complex from the medium of stomach and small intestine or will protect the platinum complex from a pH-sensitive polymer coating that allows specific colonic release of the platinum complex but is not compatible with the platinum complex.
  • Such a protective coating may be formed by a layer of at least one substance from a group comprising polysaccharides, mucopolysaccharides, proteins, oligoproteins, polyproteins, mucoproteins, peptides, oligopeptides and polypeptides, examples of which are amylose, inulin, dextrin, cyclodextrin, dextrin, dextran esters, chytosan, arabinogalactan, gum guar, glucuronate, pectin, amylopectin, polyaspartam, chondroitin, hyaluronic acid and collagen, which layer is applied in the form of an aqueous solution or an aqueous-alcoholic hydrogel and which enables protection of the platinum complex during the passage through the stomach and small intestine or protects the platinum complex from direct contact with the subsequently applied pH-sensitive polymer.
  • the weight of dry material of the applied protective coating amounts to at most 50 % by weight, based on the total weight of the granulate or tablet.
  • the thus-coated granulate or tablets may be filled into gelatin capsule which already requires no special modification or which may be subsequently coated with another protecting layer. In such case it is possible to use a hard gelatin capsule or advantageously an HPMC capsule.
  • Particularly effective protection, and thus targeted colonic application, of the platinum complex can be achieved when a granulate, coated with a layer protecting from enzymatic degradation in stomach or small intestine, or an uncoated granulate filled into hard gelatin or HPMC capsules, is coated with an outer pH-sensitive layer that dissolves only at pH 6 to 7.5, i.e. in the colonic region.
  • Preferred pharmaceutically acceptable substances enabling such coating are hydroxypropyl methyl cellulose acetate succinate (HPMCAS), methacrylic acid and its derivatives, preferably its polymers and copolymers, such as EUDRAGIT S and EUDRAGIT FS. either e.g.
  • the capsule body may also be coated by material of the protecting layer that protects from digestive enzymes in the stomach or the small intestine, used in a mixture with other polymers.
  • Polymer facilitating the coating and assisting the given antienzymatic protection, may be EC and/or MC and/or HEC and/or HPC and/or HPMC, or their mixture in a desired ratio. These mixtures are applied as aqueous or aqueous-alcoholic dispersions, the weight of the coat dry matter being less than or equal to 30 % by weight, preferably 10 to 15 % by weight, based on the total weight of the coat.
  • the dosage forms in the form of the mixture may be coated with an inert isolating layer that should protect the dosage form from the biodegradable layer or from the outer pH-sensitive colonic layer in case that no biodegradable layer has been applied.
  • This isolating layer may be e.g. formed by spraying 15 % by weight, based on the total weight of the dosage form, of hydrogel prepared by dissolution of dextran, with optional addition of glycerol as plastifier.
  • 10 % by weight of collagen or 5 % by weight of guar gum hydrogel may be used, with optional addition of glycerol as plastifier.
  • wet granulate representing one of the forms of the oral pharmaceutical composition according to the present invention
  • the wet granulate undergoes undesired chemical reactions on contact with metallic surface of conventional pharmaceutical technological equipment for processing and manufacturing solid dosage forms. This fact hinders the use of standard manufacturing techniques such as compacting in the preparation of the granulate or compressing into tablets without surface modification of the metallic parts in question. Therefore, the wet granulate, representing one of the forms of the oral pharmaceutical composition according to this invention, should be advantageously processed in an equipment whose surfaces coming into contact with the granulated mixture are inert towards the mixture. Good inert materials proved to be e.g. glass, porcelain, teflon or enamel.
  • the mentioned inert isolating layer may be damaged and thus the platinum complex might come into contact with metallic parts of the coating apparatus. This may occur particularly when the coating is carried out in a current coating equipment with metallic surfaces, such as e.g. drum coating machines, top spray fluid bed dryers, Wusters or rotoprocessors.
  • a current coating equipment with metallic surfaces such as e.g. drum coating machines, top spray fluid bed dryers, Wusters or rotoprocessors.
  • this situation can surprisingly be avoided by coating the equipment surfaces in contact with the dosage form with a film of an inert material which at the same time forms the inert isolating layer.
  • the oral pharmaceutical composition according to the invention enables one-dose application of 5 to 500 mg, preferably 50 to 350 mg, of the platinum complex of general formula I.
  • the oral pharmaceutical composition according to the invention is stable, can be easily prepared and its composition is simple.
  • the employed platinum complex of general formula I is af-bis(acetato)-b-( 1 -adamantylamine)-c-ammine-de-dichloroplatinum(IV) complex of formula II
  • This complex of summary formula C 14 H 26 Cl 2 N 2 O 4 Pt and of molecular weight 552.35 contains (acetato)-(l-adamantylamine)-ammine-trichloroplatinum(IV) complex of structural formula Pt(ac)(am)(NH 3 )Cl 3 . as principal detectable impurity.
  • the mentioned specific platinum(IV) complex of formula II, together with its antitumor effects, is described in the patent document PCT/CZ99/00015 where it is denoted as LA 12.
  • the granulate is dried at 70 0 C to humidity of 2-4 %.
  • the dry granulate is ground e.g. in a porcelain ball mill to obtain material of desired particle size.
  • the granulate, obtained according to Example 1 is filled into hard gelatin, colonic, chytosan or HPMC capsules of size ranging from 5 to 000, corresponding to the range of granulate weight from 116.55 mg to 815.85 mg, which enables dosage from 50 mg to 350 mg of the active component, or it is compacted into tablets, corresponding to analogous weights.
  • Example 3
  • the granulate is dried at 70 0 C to humidity of 2-4 %.
  • the dry granulate is ground e.g. in a porcelain ball mill to obtain material of desired particle size.
  • Component 4 is added and the mixture is mixed in a cube mixer for 15 minutes.
  • the granulate, obtained according to Example 3, is filled into hard gelatin, colonic, chytosan or HPMC capsules of size ranging from 5 to 000, corresponding to the range of granulate weight from 116.55 mg to 815.85 mg, which enables dosage from 50 mg to 350 mg of the active component, or it is compacted into tablets, corresponding to analogous weights.
  • Example S
  • the granulate is dried at 70 0 C to humidity of 2-4 %.
  • the dry granulate is ground e.g. in a porcelain ball mill to obtain material of desired particle size.
  • Inlet air temperature 50 - 70 °C
  • Nozzle diameter 0.8 mm
  • Coating layer weight 4 - 30 % by weight The spraying is executed until achieving the target weight gain of the granulate corresponding to the desired weight of the coating layer.
  • the spraying is carried out using 1% (by weight) hydrogel prepared by dissolution of dextran, with possible addition of glycerol as plasticizer.
  • glycerol as plasticizer.
  • 10% (by weight) collagen or 5% (by weight) hydrogel of quar gum may be used, with possible addition of glycerol as plasticizer.
  • the coating also may be carried out in a conventional drum coating apparatus.
  • Inlet air temperature 50 - 70 °C
  • Nozzle diameter 0.8 mm
  • Coating layer weight 5 - 30 % by weight
  • the spraying is executed until achieving the target weight gain of the dosage form, corresponding to the desired weight of the coating layer.
  • the spraying is carried out using 15% (by weight) hydrogel prepared by dissolution of dextran, with possible addition of glycerol as plasticizer.
  • glycerol as plasticizer.
  • 10% (by weight) collagen or 5% (by weight) hydrogel of quar gum may be used, with possible addition of glycerol as plasticizer.
  • the coating also may be carried out in a conventional drum coating apparatus.
  • Inlet air temperature 50 - 70 °C
  • Nozzle diameter 0.8 mm
  • Coating layer weight 8 - 12 % by weight or 6 -10 mg/cm 2 of coat dry matter
  • the spraying is executed until achieving the target weight gain of the granulate, corresponding to the desired weight of the coating layer.
  • the spraying is carried out using 20% (by weight) aqueous dispersion of Eudragit S or FS 3 or 10% (by weight) aqueous dispersion of HPMCAS.
  • the coating also may be carried out in a conventional drum coating apparatus.
  • Inlet air temperature 50 - 70 °C
  • Nozzle diameter 0.8 mm
  • Coating layer weight 8 - 12 % by weight or 6 -10 mg/cm 2 of coat dry matter
  • the spraying is executed until achieving the target weight gain of the granulate, corresponding to the desired weight of the coating layer.
  • the spraying is carried out using 20% (by weight) aqueous dispersion of Eudragit S or FS, or 10% (by weight) aqueous dispersion of HPMCAS.
  • the coating also may be carried out in a conventional drum coating apparatus.
  • Inlet air temperature 50 - 70 °C
  • Nozzle diameter 0.8 mm
  • Coating layer weight 10 - 30 % by weight
  • the spraying is executed until achieving the target weight gain of the granulate corresponding to the desired weight of the coating layer.
  • the spraying is carried out using 5% (by weight) aqueous dispersion of ethyl cellulose (Surrelease, or Aquacoat) with 10% (by weight) aqueous dispersion of amylose.
  • the coating also may be carried out in a conventional drum coating apparatus.
  • volume 900 ml
  • the test is performed for 2 hours in 0.1 M HCl, pH 1.2, then pH is adjusted to 6.8 by addition of about 20.7- g Na 3 PO 4 .12 H 2 O and the test is continued for further 8 hours.
  • the dosage form must not release more than 5 % of the active substance, after 6 hours more than 60 % of the active substance, and at least 85 % of the active substance must be released after total 12 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

L'invention concerne une composition pharmaceutique orale pour le transport ciblé de complexe de platine dans la région colorectale, comprenant un mélange de ce complexe, de formule générale I dans laquelle chaque A est indépendamment un groupe -NH<sub
PCT/CZ2005/000070 2004-09-14 2005-09-14 Composition pharmaceutique orale pour le transport cible de complexe de platine dans la region colorectale, procede de fabrication, et utilisation comme medicament WO2006029579A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT05785547T ATE491445T1 (de) 2004-09-14 2005-09-14 Orale pharmazeutische zusammensetzung für den gezielten transport eines platinkomplexes in den kolorektalbereich, verfahren zu ihrer herstellung und verwendung als medikament
US11/574,929 US7655697B2 (en) 2004-09-14 2005-09-14 Oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof
EP05785547A EP1802295B1 (fr) 2004-09-14 2005-09-14 Composition pharmaceutique orale pour le transport cible de complexe de platine dans la region colorectale, procede de fabrication, et utilisation comme medicament
JP2007531577A JP2008513383A (ja) 2004-09-14 2005-09-14 結腸直腸領域への白金錯体の標的輸送のための経口薬学的組成物、その製造方法及びその薬剤としての使用
DE602005025382T DE602005025382D1 (de) 2004-09-14 2005-09-14 Orale pharmazeutische zusammensetzung für den gezierwendung als medikament
PL05785547T PL1802295T3 (pl) 2004-09-14 2005-09-14 Doustna kompozycja farmaceutyczna do ukierunkowanego dostarczania kompleksu platyny w obszar jelita grubego, sposób jej wytwarzania i zastosowania jako lek

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20040964A CZ296459B6 (cs) 2004-09-14 2004-09-14 Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
CZPV2004-964 2004-09-14

Publications (1)

Publication Number Publication Date
WO2006029579A1 true WO2006029579A1 (fr) 2006-03-23

Family

ID=35429582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2005/000070 WO2006029579A1 (fr) 2004-09-14 2005-09-14 Composition pharmaceutique orale pour le transport cible de complexe de platine dans la region colorectale, procede de fabrication, et utilisation comme medicament

Country Status (8)

Country Link
US (1) US7655697B2 (fr)
EP (1) EP1802295B1 (fr)
JP (1) JP2008513383A (fr)
AT (1) ATE491445T1 (fr)
CZ (1) CZ296459B6 (fr)
DE (1) DE602005025382D1 (fr)
PL (1) PL1802295T3 (fr)
WO (1) WO2006029579A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007147372A3 (fr) * 2006-06-20 2008-03-13 Pliva Lachema As Préparation pharmaceutique injectable
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
US9173842B2 (en) 2007-07-11 2015-11-03 Pierre Fabre Medicament Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
US9639639B2 (en) 2010-04-27 2017-05-02 Nec Corporation Logic circuit emulator and control method therefor

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ296459B6 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP5917964B2 (ja) * 2012-03-19 2016-05-18 富士ゼロックス株式会社 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム
WO2014176389A1 (fr) 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Forme pharmaceutique solide contenant de l'arabinogalactane
JP7304128B2 (ja) 2014-06-11 2023-07-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 白金耐性の克服における使用のためのテキサフィリン－白金（ｉｖ）コンジュゲート及び組成物
RU2566290C1 (ru) * 2014-10-06 2015-10-20 Федеральное Государственное Бюджетное Учреждение Науки Институт Химии И Химической Технологии Сибирского Отделения Российской Академии Наук (Иххт Со Ран) Способ получения препарата на основе взаимодействия цис-дихлородиамминплатины(ii) с арабиногалактаном
HUE056897T2 (hu) 2015-12-09 2022-03-28 Univ Wien Med Monomaleimid-funkcionalizált platinavegyületek rákterápiához

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136336A (en) * 1997-03-17 2000-10-24 Bristol-Myers Squibb Company JM216 formulations
US6503943B1 (en) * 1998-05-27 2003-01-07 Pliva-Lachema, A.S. Platinum complex, its preparation and therapeutic application
WO2004087126A1 (fr) * 2003-03-31 2004-10-14 Pliva-Lachema A.S. Composition pharmaceutique contenant un complexe de platine utilise en tant que principe actif et procede de production associe
WO2005077357A1 (fr) * 2004-02-12 2005-08-25 Pliva-Lachema A.S. Composition pharmaceutique contenant un complexe de platine en tant que substance active, et son procede de production

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920819A (en) * 1974-12-02 1975-11-18 Lilly Co Eli Nonaqueous vehicle for oral pharmaceutical suspensions
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
DK500185A (da) * 1984-11-02 1986-05-03 Johnson Matthey Plc Oploeseliggjort platinforbindelse
JPS62207283A (ja) * 1986-03-07 1987-09-11 Yoshinori Kitani 新規な白金錯体
US5244919A (en) * 1988-02-02 1993-09-14 Johnson Matthey, Inc. Pt(IV) complexes as anti-tumor agents
US5072011A (en) * 1988-02-02 1991-12-10 Johnson Matthey, Inc. Pt(IV) complexes
US5393909A (en) * 1988-11-22 1995-02-28 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5434256A (en) * 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5196555A (en) * 1989-10-17 1993-03-23 Bristol-Myers Squibb Company Water and solvent soluble axial hydroxy and mono- and di- carboxylic acid derivatives having high tumor activity
GB9105037D0 (en) * 1991-03-09 1991-04-24 Johnson Matthey Plc Improvements in chemical compounds
US6025473A (en) * 1992-10-27 2000-02-15 Queen's University At Kingston Multidrug resistance proteins
US5409915A (en) * 1993-09-14 1995-04-25 The University Of Vermont And State Agricultural College Bis-platinum (IV) complexes as chemotherapeutic agents
JPH0817894A (ja) * 1994-06-27 1996-01-19 Dainippon Screen Mfg Co Ltd 基板表面処理装置
AU4842996A (en) * 1995-02-28 1996-09-18 Yoshinori Kidani Novel platinum (iv) complexes, process for producing the same, and carcinostatic agents containing the same
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
KR100246722B1 (ko) * 1997-12-30 2000-04-01 박호군 경구용 백금 착화합물 항암제 및 그 제조방법
CZ288406B6 (en) * 1998-05-27 2001-06-13 Lachema Np Platinum complex of oxidation number II, process for preparing such complex, the complex functioning as medicament and pharmaceutical composition in which the complex is comprised
JP2003530297A (ja) * 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｉｐアンタゴニストを用いる併用療法
BR0009780B1 (pt) * 1999-04-13 2013-09-24 processo para preparar um complexo de cisplatina
US6413953B1 (en) * 1999-04-13 2002-07-02 Anormed Inc. Pt(IV) antitumor agent
KR100317473B1 (ko) * 1999-05-11 2001-12-22 이계호 신규의 백금(ｉｖ)착제 및 그 제조방법
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
US6894049B1 (en) * 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
CA2326004A1 (fr) * 2000-11-02 2002-05-02 Richard E. Jones Methodes de traitement de troubles cellulaires proliferatifs
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
WO2004047802A2 (fr) * 2002-11-26 2004-06-10 Gilead Sciences, Inc. Formulations liposomiques
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
DE50305768D1 (de) * 2003-10-13 2007-01-04 Salama Zoser B Verfahren zur Herstellung von trans- oder cis-Diammoniumdichlorodihydroxoplatin (IV)-Salzen und -Derivaten und ihre Verwendung zur Herstellung von pharmazeutischen Wirkstoffen
EP1523984B1 (fr) * 2003-10-13 2006-12-06 Salama, Zoser B. nat.rer.Dr. Compositions pharmaceutiques comprenant l'oxoplatine et ses sels
CZ300438B6 (cs) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
CZ300125B6 (cs) * 2004-01-22 2009-02-18 Oez S. R. O. Vybavovací ústrojí, zejména pro spínací mechanismy jisticu a odpínacu
ES2308451T3 (es) * 2004-02-18 2008-12-01 Gpc Biotech Ag Satraplatino para el tratamiento de tumores resistentes o refractarios.
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
CZ2004945A3 (cs) * 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
CZ296459B6 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
JP5735724B2 (ja) * 2004-11-08 2015-06-17 インスメッド， インコーポレイテッド 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法
US7601331B2 (en) * 2004-11-10 2009-10-13 National University Of Singapore NIR-sensitive nanoparticle
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136336A (en) * 1997-03-17 2000-10-24 Bristol-Myers Squibb Company JM216 formulations
US6503943B1 (en) * 1998-05-27 2003-01-07 Pliva-Lachema, A.S. Platinum complex, its preparation and therapeutic application
WO2004087126A1 (fr) * 2003-03-31 2004-10-14 Pliva-Lachema A.S. Composition pharmaceutique contenant un complexe de platine utilise en tant que principe actif et procede de production associe
WO2005077357A1 (fr) * 2004-02-12 2005-08-25 Pliva-Lachema A.S. Composition pharmaceutique contenant un complexe de platine en tant que substance active, et son procede de production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FOKKEMA E ET AL: "Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 45, no. 1, January 2000 (2000-01-01), pages 89 - 92, XP002357878, ISSN: 0344-5704 *
RUBINSTEIN ABRAHAM: "Natural polysaccharides as targeting tools of drugs to the human colon", DRUG DEVELOPMENT RESEARCH, vol. 50, no. 3-4, July 2000 (2000-07-01), pages 435 - 439, XP009058383, ISSN: 0272-4391 *
SINHA VIVEK RANJAN ET AL: "Coating polymers for colon specific drug delivery: A comparative in vitro evaluation.", ACTA PHARMACEUTICA (ZAGREB), vol. 53, no. 1, March 2003 (2003-03-01), pages 41 - 47, XP009058380, ISSN: 1330-0075 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007147372A3 (fr) * 2006-06-20 2008-03-13 Pliva Lachema As Préparation pharmaceutique injectable
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
US9173842B2 (en) 2007-07-11 2015-11-03 Pierre Fabre Medicament Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
US9639639B2 (en) 2010-04-27 2017-05-02 Nec Corporation Logic circuit emulator and control method therefor

Also Published As

Publication number Publication date
DE602005025382D1 (de) 2011-01-27
PL1802295T3 (pl) 2011-05-31
EP1802295A1 (fr) 2007-07-04
JP2008513383A (ja) 2008-05-01
CZ2004964A3 (cs) 2006-03-15
CZ296459B6 (cs) 2006-03-15
US20070232819A1 (en) 2007-10-04
US7655697B2 (en) 2010-02-02
ATE491445T1 (de) 2011-01-15
EP1802295B1 (fr) 2010-12-15

Similar Documents

Publication Publication Date Title
EP1802295B1 (fr) Composition pharmaceutique orale pour le transport cible de complexe de platine dans la region colorectale, procede de fabrication, et utilisation comme medicament
RU2093148C1 (ru) Композиции с замедленным (пролонгированным) высвобождением
JP2773959B2 (ja) 大腸内放出性固形製剤
JP5068401B2 (ja) Ｈｐｍｃカプセルを使用する腸及び結腸への送達
KR100348585B1 (ko) 다리페나신을함유하는약학제제
EP1916995B2 (fr) Système de distribution pulsatile commandé par le ph, procédés de préparation et utilisation
JPH11506433A (ja) 結腸送達のための多重腸溶性ポリマーコーティングを有するビサコジル投与形態
JP3725539B2 (ja) ビサコジル剤形
JPH09510478A (ja) 結腸用薬剤分配組成物
US5651983A (en) Bisacodyl dosage form for colonic delivery
HRP20050902A2 (en) Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
JP2002532389A (ja) リン脂質組成物
CN104394854A (zh) 具有增强活性和降低毒性的包括硝呋替莫的硝基呋喃的新型制剂
CN102908331A (zh) 一种盐酸度洛西汀肠溶胶囊及其制备方法
Ramana Preparation and In-vitro characterization of ethylcellulose coated pectin alginate microspheres of 5-fluorouracil for colon targeting
WO2005077357A1 (fr) Composition pharmaceutique contenant un complexe de platine en tant que substance active, et son procede de production
RU2116785C1 (ru) Оральная лекарственная форма, растворимая в толстой кишке, и материал оболочки для нее
JP3122478B2 (ja) 下部消化管放出型経口製剤
CN1232386A (zh) 弱酸药物的结肠运送
JP3592723B2 (ja) 非崩壊・持続性カプセル製剤
JP3004663B2 (ja) 徐放性フレカイニドアセテート製剤
WO1998024412A2 (fr) Composes convenant au traitement de colopathies et procedes d&#39;administration orale de ces composes
CN100355422C (zh) 含有铂络合物作为活性物质的药物组合物及其制备方法
AU2004226898B2 (en) Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
JPS6310719A (ja) 徐放性カプセル剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007232819

Country of ref document: US

Ref document number: 11574929

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007531577

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005785547

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005785547

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11574929

Country of ref document: US